Clinical Trial Update: Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms [Phase 4]

View source ↗

Summary

Open-label Phase 4 study evaluating safety and efficacy of SPN-812 (viloxazine extended-release) in adults with ADHD and mood symptoms; results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• SPN-812 (viloxazine)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Attention-Deficit/Hyperactivity Disorder | Phase 4 | Status: COMPLETED | Results posted: 2026-03-06